Research

CTNC has a tradition of excellence in clinical research, having participated in over 50 clinical trials. All of us at CTNC want our patients to be aware of our dedication to clinical research. Our physicians have extensive experience and are committed to advancing medical science through clinical research studies.

What is Clinical Research?

The National Institutes of Health defines “clinical research” as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual.Clinical research includes:

Patient-oriented research – This type of research involves a particular person or group of people, or uses materials from humans. This research can include 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies

Epidemiological and behavioral studies – These types of studies examine the distribution of disease, the factors that affect health, and how people make health-related decisions.

Outcomes and health services research – These studies seek to identify the most effective and most efficient interventions, treatments, and services.

ACTIVE TRIALS: ENROLLING

Essential Tremors:

Progressive
Supranuclear Palsy:

a35-009

A Phase 3 study of safety and efficacy in AMX0035 in Progressive Supranuclear Palsy.

Status: Open Enrollment

FNP223-CT-2301

A randomized, double-blind placebo-controlled, study to asses the safety Efficacy, and pharmacokinetics of FNP-223 (oral formulation) for the treatment of Progressive Supranuclear Palsy.

Status: Open Enrollment

Alzheimer's Disease:

Parkinson's Disease:

PD0060

A Multicenter Phase 2, Double-Blind, Placebo-controlled, Randomized, Parallel group study to evaluate the efficacy, safety, tolerability and Pharmacokinetics or UCB0022 in study participants with advanced PD

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

CVN424-203

A randomized, Double-Blind, Placebo-controlled Trial of CVN424 in Early Parkinson's Disease.

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

283PD201

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo Controlled Study to determine the efficacy and safety of BIIB122 in participants with Parkinson's Disease

Status: Open Enrollment

Study Overview

Principal Investigator:
Dr. Peckham

ACTIVE TRIALS: ONGOING

Essential Tremors:

324-ETD-202

Phase 2 Double-blind, Randomized, Placebo-Controlled, Dose-Response Study of SAGE-324 for the Treatment of Essential Tremor

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

Alzheimer's Disease:

J1G-MC-LAKC

Assessment of safety and efficacy measured by amyloid reduction of remternetug in early symptomatic Alzheimer's disease.

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

I5T-MC-AACI

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease.

Status: Ongoing | Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

Parkinson's Disease:

IKT-148009-201

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

Status: Ongoing |Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

BP 39529

A Randomized, Double-Blind, Placebo-Controlled 52 week phase II Study to evaluate the efficacy of IV RO7046015 (PRX002) in participants with early Parkinson's Disease.

Status: Ongoing |Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

BN42358

A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multi-center study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson's Disease.

Status: Ongoing |Not Enrolling

Study Overview

Principal Investigator:
Dr. Peckham

UPCOMING TRIALS:

CLIN-10200-455

A Phase II, multi-center, randomized, double-blind, placebo-controlled Sequential Cohort Study to evaluate the efficacy and safety of two single doses of IPN10200 for the Treatment of Blepharospasm in Adults.

Lundbeck 20303 A

A multi-site, randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of 22 week oral treatment with LuAF28996 in participants with Parkinson's Disease.

CVN-424-301

Phase 3 study in Parkinson's Disease patients with Motor Complications.

NR-103A-01-IPS-3001

A Phase 3, randomized, double-blind, parallel-group, active-comparator, multi-center study to evaluate the safety of Proposed Biosimilar (MR-103A-01) Compared to OnabotullinumtoxinA (Botox) in Moderate to Severe Cervical Dystonia.
A seamless Phase 2A-Phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of Benfotiamine in patients with early Alzheimer's Disease (BenfoTeam).

AR1001-ADP3-US01

A Phase 3 double-blind, randomized, placebo-controlled, multi-center trial to evaluate the efficacy and safety of AR1001 over 52 weeks in participants with early Alzheimer's Disease.

vent-02-102

A randomized, double-blind, placebo- controlled, phase 1B study of the NLRP3 inhibitor Vent-02 in patients with mild to moderate Parkinson's Disease.

RESEARCH TEAM